Mouse-adapted influenza B virus for in vitro and in vivo assessment of therapeutic and preventive efficacy of antiviral drugs

Objective: to develop a new antigenic relevance influenza B virus suitable for modeling influenza infection in mice to assess of in vivo and in vitro therapeutic and preventive efficacy of antiviral drugs.

Materials and methods: was carried out an adaptation of influenza B virus in BALB/c mice. Was performed, comparative assessment of in vivo and in vitro pathogenicity of the parenta! virus and. adapted, influenza B virus. Was assessed, inhibition of neuraminidase with antiviral drugs (oseltamivir ethoxyacrylate and. Tamiflu) in relation to the adapted, influenza B virus.

Results: adapted  influenza B virus (B/Novosibirsk/40/2017-MA strain) models non-lethal influenza infection with pronounced, clinical signs of the disease in experimental animals. Were described the destructive changes in lungs and. brain that increases during infection. Analysis of internal organs (lungs, brain, liver, heart, kidneys, spleen) were revealed viral load only in the lungs. Were evaluated, in vivo and in vitro efficacy of antiviral drugs (oseltamivir ethoxysuccinate and Tamiflu®) on the model of influenza infection. Were proved, the high, efficiency of the innovative drug — oseltamivir ethoxysuccinate.

Conclusion: the antigen-relevant adapted, influenza B virus (B/Novosibirsk/40/2017-MA strain) can be used, to assess the drug effectiveness against influenza, as well as an additional tool for predicting the effectiveness of the vaccine against drifting strains.

1. Bodewes, R. Recurring influenza B virus infections in seals / R. Bodewes, D. Morick, G. de Mutsert et al. // Emerging infectious diseases. — 2013. — № 19(3). — P. 511-2

2. Osterhaus AD, Rimmelzwaan GF, Martina BE, et al. Influenza B virus in seals. Science, 2000;288(5468):1051-1053.

3. Su S, Chaves SS, Perez A, et al. Comparing clinical characteristics between hospitalized adults with laboratory-confirmed influenza A and B virus infection. Clin. Infect. Dis., 2014;59(2):252-255.

4. Chen M. World at the beginning of the 2009 influenza pandemic. WHO. Who Director-General Dr Margaret Chan's press statement 11 June 2009 ghttps://www.who.int/mediacentre/news/statements/2009/h1n1_pandemic_phase6_20090611/ru/ (01.07.2009)

5. Adlhoch C, Snacken R, Melidou A, et al. The European Influenza Surveillance Network. Dominant influenza A(H3N2) and B/Yamagata virus circulation in EU/EEA, 2016/17 and 2017/18 seasons, respectively. Euro Surveill. 2018;23(13):pii=18-00146. https://doi.org/10.2807/1560-7917.ES.2018.23.13.18-00146

6. ICTV. International Committee on Taxonomy of Viruses. — 2019. — http://www.Ictvonline.org/virusTaxonomy.asp

7. Chen R, Holmes EC. Avian influenza virus exhibits rapid evolutionary dynamics. Mol. Biol. Evol., 2006; 23(12):2336-2341.

8. McCullers JA, Hoffmann E, Huber VC, et al. A single amino acid change in the C-terminal domain of the matrix protein M1 of influenza B virus confers mouse adaptation and virulence. Virology, 2005;336(2):318 — 326.

9. McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clinical microbiology reviews, 2006;19(3):571—582.

10. Jain A, Dangi T, Jain B, et al. Genetic changes in influenza A(H3N2) viruses circulating during 2011 to 2013 in northern India (Lucknow). J Med. Virol., 2015;87(8):1268-1275.

11. Rota PA, Rocha ER, Harmon MW, et al. Laboratory characterization of a swine influenza virus isolated from a fatal case of human influenza. Journal of clinical microbiology, 1989;27(6):1413-1416.

12. Shaw MW, Xu X, Li Y, et al. Reappearance and global spread of variants of influenza B/Victoria/2/87 lineage viruses in the 2000-2001 and 2001-2002 seasons. Virology, 2002;303(1):1-8.

13. Kim E, Park S, Kwon H, et al. Mouse adaptation of influenza B virus increases replication in the upper respiratory tract and results in droplet transmissibility in ferrets. Scientific Reports, 2015;11(5):1-14.

14. Manual for the laboratory diagnosis and virological surveillance of influenza. WHO Global Influenza Surveillance Network, 2011. 153p.

15. Ashmarin I.P., Vorobjev A.A. Statistical methods in microbiological research. L.: Medgiz., 1962. 182 p. (In Russ.)

16. Patent for the invention of the Russian Federation № 2639158 Ethyl (3S,4R,5S)-4-acetamido-5-amino-3-(1-ethylpro-poxy)cyclohex-1-EN-1-carboxylate ethoxysuccinate as an antiviral drug and a method for its preparation, publ. 20.12.2017, IPC C07C 233/52, A61K 31/16, A61P 31/12.

17. Gubareva LV, Webster RG, Hayden FG. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antiviral Res. 2002;53(1):47 — 61.

18. ISIRV. 2014. Panel of influenza A and B viruses is for the assessment of neuraminidase inhibitor susceptibility. https://isirv.org/site/images/AVG_panel_leaflet_Nov14.pdf. Accessed February 2016

19. Zhang C, Zhao Z, Guo Z, et al. Amino Acid Substitutions Associated with Avian H5N6 Influenza A Virus Adaptation to Mice. Front. Microbiol. 8:1763. doi: 10.3389/fmicb.2017.01763

20. Patent for the invention of the Russian Federation № 2105063 strain of INFLUENZA B virus (Leningrad) 14/76/50, designed to produce harmless and highly productive influenza B viruses for the production of inactivated and live influenza vaccines, publ. 20.02.1998, IPC C12N 7/00, A61K 39/145.

21. Patent for the invention of the Russian Federation № 2215786 Strain of influenza B/60/ Johannesburg/99/50 for the production of live influenza intranasal vaccine for adults and children, publ. 10.11.2003, IPC IPC C12N 7/00, A61K 39/145.

22. Patent for the invention of the Russian Federation № 2307161 Strain of influenza B/60/Jilin/03/1 for the production of live influenza intranasal vaccine for adults and children, publ date. 27.09.2007. IPC C12N 7/00, A61K 39/145.

23. Patent for the invention of the Russian Federation № 2605926 Strain of influenza B/60/Phuket/2013/26 for the production of live influenza intranasal vaccine for adults and children, publ. 27.12.2016, IPC C12N 7/00, A61K 39/145, A61Z 31/16.

24. Patent for the invention RF № 25229772 Holodnode-formirovannye strain of the flu virus In In Victoria/2/63/87 intended as strain-donor of attenuation for obtaining reassortants holodnodeformirovannyh strains for live influenza vaccine, publ. 27.09.2014, IPC C12N 7/00, A61K 39/145.

25. Boianelli A, Nguyen VK, Ebensen T, et al. Modeling Influenza Virus Infection: A Roadmap for Influenza Research Viruses. 2015;7(10): 5274 — 5304. doi: 10.3390/v7102875

26. Groves HT, McDonald JU, Langat P, et al. Mouse Models of Influenza Infection with Circulating Strains to Test Seasonal Vaccine Efficacy. Front. Immunol. 2018;9:126. doi: 10.3389/fimmu.2018.00126

27. Santos JJS, Finch C, Sutton T, et al. Development of an alternative modified live influenza B virus vaccine. J. Virol. 2017, doi:10.1128/JVI.00056-17

28. Asahi Y, Yoshikawa T, Watanabe I, et al. Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines. J. Immunol., 2002;168(6):2930-2938.

29. Sakai K, Ami Y, Nakajima N, et al. TMPRSS2 Independency for Haemagglutinin Cleavage In Vivo Differentiates Influenza B Virus from Influenza A. Virus. Sci Rep., 2016;6: 1-10.

30. WHO. (2018). http://www.euro.who.int/ru/health-topics/communicable-diseases/influenza/seasonal-influenza/clinical-management/about-antiviral-drugs

31. Burceva E. Review of efficacy data and monitoring of os-eltamivir susceptibility to influenza virus strains. Vrach = Doctor, 2010, no. 12, pp 67-70.